Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Pro

Showing results (161-170 of 187) with videos related to

Pageof 19
Sort By:
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 16, 2011
Hodgkin lymphomaRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Lancet (London, England)|December 8, 2018
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven Horwitz, Owen A O'Connor, Barbara Pro, et al.
Blood|June 11, 2021
Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneityJoonhee Park, Jay Daniels, Tim Wartewig, et al.
Cancer|January 30, 2019
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort studySteven I Park, Steven M Horwitz, Francine M Foss, et al.
Cancer|December 3, 2016
A prospective cohort study of patients with peripheral T-cell lymphoma in the United StatesKenneth R Carson, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelinesRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Blood Neoplasia|October 23, 2025
Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemiaEvelyn H Orlando, Patrick Gould, Brian Cuzzo, et al.
Pageof 19

Showing results (161-170 of 187) with videos related to

Sort By:
Pageof 19
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 16, 2011
Hodgkin lymphomaRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Lancet (London, England)|December 8, 2018
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven Horwitz, Owen A O'Connor, Barbara Pro, et al.
Blood|June 11, 2021
Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneityJoonhee Park, Jay Daniels, Tim Wartewig, et al.
Cancer|January 30, 2019
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort studySteven I Park, Steven M Horwitz, Francine M Foss, et al.
Cancer|December 3, 2016
A prospective cohort study of patients with peripheral T-cell lymphoma in the United StatesKenneth R Carson, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelinesRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Blood Neoplasia|October 23, 2025
Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemiaEvelyn H Orlando, Patrick Gould, Brian Cuzzo, et al.
Pageof 19